1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Asswood

Discussion in 'Caswood' started by Anonymous, Jul 20, 2011 at 9:34 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Watch out for those nasty splinters!
     
  2. Anonymous

    Anonymous Guest

    Can Asswood reps produce harder woodies?
     
  3. Anonymous

    Anonymous Guest

    let the good times role!
     
  4. Anonymous

    Anonymous Guest

    Asswood is harder than steel !